Biochemotherapy for melanoma: Rational therapeutics in the search for weapons of melanoma destruction

Cancer

Volumn 101, Issue 3, 2004, Pages 435-438

  Margolin, Kim A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 LIGAND; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; ENDOTHELIAL CELL GROWTH FACTOR; FK 506 BINDING PROTEIN; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; OBLIMERSEN; RAS PROTEIN; RIBOSOME PROTEIN; SORAFENIB; TAMOXIFEN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VINBLASTINE; VINDESINE;

ANGIOGENESIS; APOPTOSIS; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; HELPER CELL; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL RESPONSE MODIFIERS; DRUG THERAPY, COMBINATION; HUMANS; MELANOMA; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3242798969     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20402     Document Type: Review

References (13)

1. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997;15:2579-2588.
2. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17: 968-975.
3. Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter Phase III randomized clinical trial. J Clin Oncol. 2002;20:1600-1607.
4. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a Phase III randomized trial. J Clin Oncol. 2002; 20:2045-2052.
5. Keilholz U, Punt CJ, Gore M, et al. Dacarbazine, cisplatin and IFN-α2b with or without IL-2 in advanced melanoma: final analysis of EORTC randomized Phase III trial 18951 [abstract]. Proc Am Soc Clin Oncol. 2003;22:708.
6. Del Vecchio M, Bajetta E, Vitali M, et al. Multicenter Phase III randomized trial of cisplatin, vindesine and dacarbazine alpha-2b (IFN) in metastatic melanoma patients (pts) [abstract]. Proc Am Soc Clin Oncol. 2003;22:709.
7. Atkins MB, Lee S, Flaherty LE, et al. A prospective randomized Phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial [abstract]. Proc Am Soc Clin Oncol. 2003;22:708.
8. Kim KB, Eton O, East MJ, et al. Pilot study of high-dose concurrent biochemotherapy for advanced melanoma. Cancer. 2004;101:596-603.
9. Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000;6:3895-3903.
10. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-540.
11. Carr KM, Bittner M, Trent JM. Gene-expression profiling in human cutaneous melanoma. Oncogene. 2003;22:3076-3080.
12. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586.
13. Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002;3:RESEARCH0035.